Anúncio
Anúncio

NRXP

NRXP logo

NRX Pharmaceuticals, Inc. Common Stock

2.33
USD
Patrocinado
-0.12
-5.02%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

2.35

+0.02
+0.77%

Relatórios de Lucros NRXP

Rácio de surpresa positiva

NRXP separação 7 de 14 últimas estimativas.

50%

Próximo Relatório

Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$9.51M
/
$0.00
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+3830.37%
/
-100.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-100.00%

NRX Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 14 de nov. de 2025, NRXP reported earnings of -0.50 USD per share (EPS) for Q3 25, missing the estimate of -0.08 USD, resulting in a -476.70% surprise. Revenue reached 242.00 mil, compared to an expected 6.96 milhão, with a -96.52% difference. The market reacted with a -15.26% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of 0.00 USD, with revenue projected to reach 9.51 milhão USD, implying an diminuir of -100.00% EPS, and aumentar of 3830.37% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, NRX Pharmaceuticals, Inc. Common Stock reported EPS of -$0.50, missing estimates by -476.7%, and revenue of $242.00K, -96.52% below expectations.
The stock price moved down -15.26%, changed from $2.49 before the earnings release to $2.11 the day after.
The next earning report is scheduled for 16 de mar. de 2026.
Based on 6 analistas, NRX Pharmaceuticals, Inc. Common Stock is expected to report EPS of -- and revenue of $9.51M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio